Vertex Pharmaceuticals has signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for its cystic fibrosis treatment, ALYFTREK. This agreement marks a crucial step towards securing market access and reimbursement for the drug across Canada.
Vertex Signs LOI with Canadian Alliance for Cystic Fibrosis Drug ALYFTREK
|1 min read
Vertex PharmaceuticalsVRTXALYFTREKCystic FibrosisPharmaceuticalsCanada